Bevacizumab
Avastin (bevacizumab) is an antibody pharmaceutical. Bevacizumab was first approved as Avastin on 2004-02-26. It is used to treat colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, and non-small-cell lung carcinoma amongst others in the USA. It has been approved in Europe to treat breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, non-small-cell lung carcinoma, and ovarian neoplasms amongst others. The pharmaceutical is active against vascular endothelial growth factor A.
Trade Name | Avastin |
---|---|
Common Name | Bevacizumab |
ChEMBL ID | CHEMBL1201583 |
Indication | breast neoplasms, colorectal neoplasms, fallopian tube neoplasms, glioblastoma, kidney neoplasms, non-small-cell lung carcinoma, ovarian neoplasms, peritoneal neoplasms, renal cell carcinoma, uterine cervical neoplasms |
Drug Class | Monoclonal antibodies: humanized, cardiovascular indications |
